Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion type Assertion NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_head.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion wasGeneratedBy ECO_0000203 NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_provenance.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion wasDerivedFrom befree-2016 NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_provenance.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion SIO_000772 14633710 NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_provenance.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion evidence source_evidence_literature NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_provenance.
- NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_assertion description "[Antitumor effects of a soluble form dominant negative of the type I insulin-like growth factor receptor (IGF-IR) designated as 486/STOP were evaluated in CaOV-3 human ovarian cancer cells by establishing stable transformants overexpressing 486/STOP and by administration of 486/STOP recombinant protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421703.RAK20wcvrqq0MuYm65vG9K31eyVbA-BeEdJF-acT_kHXQ130_provenance.